Skip to Content

Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide) Disease Interactions

There are 8 disease interactions with Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide):

Major

Calcium Salts (Includes Dual Action Complete) ↔ Calcium- Phosphate Calcifications

Severe Potential Hazard, High plausibility

Applies to: Phosphate Imbalance

Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
Major

Calcium Salts (Includes Dual Action Complete) ↔ Cardiac Contraction/Conduction

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias

Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.

References

  1. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  2. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Major

Calcium Salts (Includes Dual Action Complete) ↔ Malabsorption

Severe Potential Hazard, High plausibility

Applies to: Achlorhydria, Malabsorption Syndrome

Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.

References

  1. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
Major

Calcium Salts (Includes Dual Action Complete) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
Major

Calcium Salts (Includes Dual Action Complete) ↔ Sarcoidosis

Severe Potential Hazard, High plausibility

Applies to: Sarcoidosis

Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.

References

  1. "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Posture (calcium phosphate, triphasic)." Whitehall-Robbins, Madison, NJ.
  3. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
Major

H2 Antagonists (Includes Dual Action Complete) ↔ Gi Bleeding

Severe Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

Major

Magnesium Salts (Includes Dual Action Complete) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.

References

  1. "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine, Erlanger, KY.
  2. "Product Information. Losospan (magaldrate)." Whitehall-Robbins, Madison, NJ.
  3. "Product Information. Slow-Mag (magnesium chloride)." Searle, Skokie, IL.
  4. "Product Information. Uro-Mag (magnesium oxide)." Blaine, Erlanger, KY.
  5. "Product Information. Magonate (magnesium gluconate)." Fleming and Company, Fenton, MO.
View all 5 references
Moderate

Famotidine (Includes Dual Action Complete) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous). The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients. Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients. Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient's clinical response.

References

  1. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987): 782-7
  2. Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
  3. Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987): 458-63
  4. Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985): 327-31
  5. "Product Information. Pepcid (famotidine)." Merck & Co, Inc, West Point, PA.
  6. Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988): 656-63
  7. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988): 315-21
View all 7 references

Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide) drug Interactions

There are 724 drug interactions with Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide)

Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide) alcohol/food Interactions

There is 1 alcohol/food interaction with Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide)

More about Dual Action Complete (calcium carbonate / famotidine / magnesium hydroxide)

Related treatment guides

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide